Thrombin-activatable fibrinolysis inhibitor protects against acute lung injury by inhibiting the complement system

American Journal of Respiratory Cell and Molecular Biology

Volumn 49, Issue 4, 2013, Pages 646-653

  Naito, Masahiro ^a,b   Taguchi, Osamu ^a   Kobayashi, Tetsu ^a   Takagi, Takehiro ^a   D'Alessandro Gabazza, Corina N ^a   Matsushima, Yuki ^a   Boveda Ruiz, Daniel ^a   Gil Bernabe, Paloma ^a   Matsumoto, Takahiro ^a   Chelakkot Govindalayathil, Ayshwarya Lakshmi ^a   Toda, Masaaki ^a   Yasukawa, Atsushi ^a   Hataji, Osamu ^b   Morser, John ^c   Takei, Yoshiyuki ^a   Gabazza, Esteban C ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Matsusaka Municipal Hospital   (Japan)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coagulation; Fibrinolysis; Inflammation; Lung injury

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; OSTEOPONTIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; COMPLEMENT SYSTEM; CONTROLLED STUDY; FIBRINOLYSIS; INFLAMMATORY CELL; KNOCKOUT MOUSE; LUNG ALVEOLUS CELL; LUNG INFILTRATE; LUNG LAVAGE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PLASMA CELL; WILD TYPE;

ACUTE LUNG INJURY; ANIMALS; BLOOD COAGULATION; BRONCHOALVEOLAR LAVAGE FLUID; CARBOXYPEPTIDASE U; COMPLEMENT C5A; CYTOKINES; FIBRINOLYSIS; INFLAMMATION; LIPOPOLYSACCHARIDES; LUNG; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHILS; PNEUMONIA; THROMBIN;

EID: 84886473588     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0454OC     Document Type: Article

References (30)

1. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin definition. JAMA 2012;307:2526-2533.
2. Villar J, Blanco J, Anon JM, Santos-Bouza A, Blanch L, Ambros A, Gandia F, Carriedo D, Mosteiro F, Basaldua S, et al. The alien study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. Intensive Care Med 2011;37:1932-1941.
3. WalkeyAJ, Summer R, Ho V, Alkana P. Acute respiratory distress syndrome: epidemiology and management approaches. Clin Epidemiol 2012;4:159-169.
4. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. Incidence and outcomes of acute lung injury. N Engl J Med 2005;353:1685-1693.
5. Cross LJ, Matthay MA. Biomarkers in acute lung injury: insights into the pathogenesis of acute lung injury. Crit Care Clin 2011;27:355-377.
6. Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol 2011;6:147-163.
7. Colucci M, Semeraro N. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation. Thromb Res 2012;129:314-319.
8. Morser J, Gabazza EC, Myles T, Leung LL.What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse? J Thromb Haemost 2010;8:868-876.
9. Heylen E, Willemse J,Hendriks D.An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis. Front Biosci 2011;16:2427-2450.
10. Campbell WD, Lazoura E, Okada N, Okada H. Inactivation of c3a and c5a octapeptides by carboxypeptidase r and carboxypeptidase n. Microbiol Immunol 2002;46:131-134.
11. FujiwaraA, TaguchiO, Takagi T,D'Alessandro-Gabazza CN, Boveda-RuizD, Toda M, Yasukawa A, Matsushima Y, Miyake Y, Kobayashi H, et al. Role of thrombin-activatable fibrinolysis inhibitor in allergic bronchial asthma. Lung 2012;190:189-198.
12. Song JJ, Hwang I, Cho KH, Garcia MA, Kim AJ, Wang TH, Lindstrom TM, Lee AT, Nishimura T, Zhao L, et al. Plasma carboxypeptidase b downregulates inflammatory responses in autoimmune arthritis. J Clin Invest 2011;121:3517-3527.
13. Finch AM, Wong AK, Paczkowski NJ, Wadi SK, Craik DJ, Fairlie DP, Taylor SM. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor c5a. J Med Chem 1999;42:1965-1974.
14. Paczkowski NJ, Finch AM,Whitmore JB, Short AJ, Wong AK,Monk PN, Cain SA, Fairlie DP, Taylor SM. Pharmacological characterization of antagonists of the c5a receptor. Br J Pharmacol 1999;128:1461-1466.
15. Nagashima M, Yin ZF, Zhao L, White K, Zhu Y, Lasky N, Halks-Miller M, Broze GJ Jr, Fay WP, Morser J. Thrombin-activatable fibrinolysis inhibitor (tafi) deficiency is compatible with murine life. J Clin Invest 2002;109:101-110.
16. Burrell R, Lantz RC, Hinton DE.Mediators of pulmonary injury induced by inhalation of bacterial endotoxin. Am Rev Respir Dis 1988;137:100-105.
17. Rittirsch D, Flierl MA, Day DE, Nadeau BA, McGuire SR, Hoesel LM, Ipaktchi K, Zetoune FS, Sarma JV, Leng L, et al. Acute lung injury induced by lipopolysaccharide is independent of complement activation. J Immunol 2008;180:7664-7672.
18. Kruithof EK. Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins. Thromb Haemost 2008;100:969-975.
19. Kambas K, Markiewski MM, Pneumatikos IA, Rafail SS, Theodorou V, Konstantonis D, Kourtzelis I, Doumas MN, Magotti P, Deangelis RA, et al. C5a and tnf-alpha up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome. J Immunol 2008;180:7368-7375.
20. Hammerschmidt DE, Weaver LJ, Hudson LD, Craddock PR, Jacob HS. Association of complement activation and elevated plasma-c5a with adult respiratory distress syndrome: pathophysiological relevance and possible prognostic value. Lancet 1980;1:947-949.
21. Pittet JF, Mackersie RC, Martin TR, Matthay MA. Biological markers of acute lung injury: prognostic and pathogenetic significance. Am J Respir Crit Care Med 1997;155:1187-1205.
22. Solomkin JS, Cotta LA, Satoh PS, Hurst JM, Nelson RD. Complement activation and clearance in acute illness and injury: evidence for c5a as a cell-directed mediator of the adult respiratory distress syndrome in man. Surgery 1985;97:668-678.
23. Zimmerman JL, Dellinger RP, Straube RC, Levin JL. Phase i trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit Care Med 2000;28: 3149-3154.
24. Allegretti M, Moriconi A, Beccari AR, Di Bitondo R, Bizzarri C, Bertini R, Colotta F. Targeting c5a: recent advances in drug discovery. Curr Med Chem 2005;12:217-236.
25. Bolger MS, Ross DS, Jiang H, Frank MM, Ghio AJ, Schwartz DA,Wright JR. Complement levels and activity in the normal and lps-injured lung. Am J Physiol Lung Cell Mol Physiol 2007;292:L748-L759.
26. Rabinovici R, Yeh CG, Hillegass LM, Griswold DE, DiMartino MJ, Vernick J, Fong KL, Feuerstein G. Role of complement in endotoxin/ platelet-activating factor-induced lung injury. J Immunol 1992;149: 1744-1750.
27. MeduriGU,Headley S, Kohler G, Stentz F, Tolley E, Umberger R, Leeper K. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS: plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995;107:1062-1073.
28. Pugin J, Ricou B, Steinberg KP, Suter PM, Martin TR. Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent role for interleukin-1. Am J Respir Crit Care Med 1996; 153:1850-1856.
29. Sebag SC, Bastarache JA, Ware LB. Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome. Curr Pharm Biotechnol 2011;12: 1481-1496.
30. Nishimura T, Myles T, Piliponsky AM, Kao PN, Berry GJ, Leung LL. Thrombin-activatable procarboxypeptidase b regulates activated complement c5a in vivo. Blood 2007;109:1992-1997.